Use of prostaglandins F2Alpha and analogues for the healing of corneal and conjunctival lesions
The invention relates to a composition for use in treating corneal and conjunctival lesions, wherein the composition comprises a prostaglandin F2alpha or analogue, in a therapeutic amount, said composition being in a form suitable for topical application on the ocular surface and is free of deleterious preservative; the invention also relates to a method for treating surface ocular conditions in a patient in need thereof, comprising administering a composition of the invention.
1. A composition comprising a therapeutic amount of prostaglandin F2alpha or an analogue thereof in a form suitable for topical application to an ocular surface, wherein said therapeutic amount is a concentration of prostaglandin F2alpha or analogue from 0.0001 to 0.005% by weight of the composition.
2. The composition of claim 1 , further defined as being free of a deleterious preservative.
3. The composition of claim 1 , further defined as an aqueous solution, a viscous or semi-viscous gel, a suspension, a solid insert, or an anionic or cationic emulsion.
4. The composition of claim 1 , further defined as eye drops, artificial tears, gel, or ointment.
5. The composition of claim 1 , further defined as sterile.
6. The composition of claim 1 , further defined as isoosmotic or hypoosmotic.
7. The composition of claim 1 , further comprising an osmoprotectant or other healing agent.
8. The composition of claim 1 , comprising a prostaglandin F2alpha analogue that is further defined as latanoprost, acid free latanoprost, 15-keto-latanoprost, latanoprost nitroxide unoprostone, bimatoprost, travoprost, or tafluprost.
9. The composition of claim 1 , wherein the therapeutic amount is a concentration of prostaglandin F2alpha or analogue from 0.0001 to less than 0.005% by weight of the composition.
10. The composition of claim 9 , wherein the therapeutic amount is a concentration of prostaglandin F2alpha analogue from 0.0001 to than 0.002% by weight of the composition.
11. The composition of claim 1 , further defined as unpreserved, preservative-free, self-preserved, or preserved with soft preservatives.
12. The composition of claim 1 , further comprising an anti-glaucoma agent, anti-inflammatory agent, an antibiotic, an antiviral, an antifungal, and/or a secretagogue.
13. The composition of claim 1 , further comprising a buffer, thickening agent, moisturizing agent and/or antioxidant.
14. A method of treatment of a surface ocular condition comprising:
obtaining a composition of claim 1 ; and
administering the composition to a patient;
wherein a surface ocular condition in the patient is treated.
15. The method of claim 14 , wherein the surface ocular condition is a corneal or conjunctival lesion.
16. The method of claim 14 , further defined as comprising administering the composition at least once per day, with a maximum of four instillations per day, wherein the therapeutic amount of the prostaglandin F2alpha or analogue is 0.0001 to 0.005% by weight of the composition.
17. The method of claim 14 , wherein the patient is affected by glaucoma and the therapeutic amount of the prostaglandin F2alpha or analogue is 0.004 to 0.005% by weight of the composition.
18. The method of claim 14 , wherein the patient is not affected by glaucoma, the therapeutic amount of the prostaglandin F2alpha or analogue is 0.0001% to 0.004% by weight of the composition, and the composition is administered for three to five days.